HMCN1 Antibody

What is HMCN1 and why is it important in research?

HMCN1 (Hemicentin 1), also known as fibulin-6, is a large extracellular matrix (ECM) protein belonging to the immunoglobulin superfamily. The canonical protein has 5635 amino acid residues with a molecular mass of approximately 613.4 kDa. HMCN1 is structurally characterized by:

• An N-terminal von Willebrand factor A (VWFA) domain

• A hemicentin motif

• A long stretch (>40) of tandem immunoglobulin (Ig) domains

• A G2F domain associated with multiple EGF domains

• A fibulin C-terminal module domain

HMCN1 is important in research due to its roles in:

• Cell migration, invasion, and metastasis in cancer models

• Basement membrane formation and integrity

• Contribution to extracellular matrix architecture

• Association with various pathological conditions including cancer and certain genetic disorders

What are the main subcellular localizations of HMCN1?

HMCN1 exhibits multiple subcellular localizations that are important to consider when designing immunodetection experiments:

In mouse tissues, HMCN1 has been detected as fine tracks along the basement membrane of hair and whisker follicles, in the sclera of the eyes, in the lumen of some lymphoid conduits, and in the mesangial matrix of kidney glomeruli . Proper fixation techniques are critical to preserve HMCN1's extracellular structure during immunodetection procedures.

How should researchers validate HMCN1 antibodies for experimental use?

Validation of HMCN1 antibodies is crucial due to the protein's large size and multiple isoforms. A comprehensive validation approach should include:

• Knockout/knockdown validation: Use tissues/cells from HMCN1 knockout mice as negative controls to confirm antibody specificity. Multiple studies have validated antibodies using CRISPR/Cas9-mediated Hmcn1 knockout mice .

• Multiple epitope targeting: Use antibodies raised against different regions of HMCN1:

  • N-terminal VWA domain

  • Thrombospondin type (TSP) 1 repeats

  • G2 nidogen domain

  • C-terminal EGF and fibulin type modules

• Multiple detection techniques: Cross-validate using different methodologies:

• Isoform awareness: Recognize that antibodies may detect all three HMCN1 isoforms differently depending on the epitope targeted .

What considerations should be made when choosing between commercially available HMCN1 antibodies?

When selecting an HMCN1 antibody, researchers should consider:

• Target epitope location: Different domains of HMCN1 may be more accessible in certain experimental conditions:

  • Antibodies against the C-terminus or VWA domain have shown consistent pattern of immunoreactivity in multiple tissues

  • Domain-specific antibodies enable study of specific protein regions

• Validated applications: Choose antibodies with published validation in your specific application:

• Species reactivity: Consider cross-reactivity with model organism HMCN1:

  • Human HMCN1 antibodies may not equally detect mouse or rat orthologs

  • HMCN1 orthologs have been reported in mouse, rat, bovine, frog, zebrafish, chimpanzee, and chicken

• Independent validation evidence: Look for antibodies with multiple citations and validation data in peer-reviewed publications .

What are the optimal methods for detecting HMCN1 expression in tissue samples?

Detection of HMCN1 in tissue samples requires careful methodology due to its extracellular localization and large size:

• Immunohistochemistry (IHC) protocol optimization:

  • Fixation: 4% paraformaldehyde is preferred over harsher fixatives

  • Antigen retrieval: TE buffer pH 9.0 provides optimal results for many antibodies

  • Blocking: Extended blocking (1-2 hours) with serum matching secondary antibody species

  • Primary antibody: Overnight incubation at 4°C at dilutions between 1:20-1:200

  • Controls: Include Hmcn1 knockout tissue as negative control

• Tissues showing consistent HMCN1 detection:

• Co-localization studies: Combine HMCN1 detection with markers of:

  • Basement membranes (collagen IV, nidogen)

  • Extracellular matrix (collagen I)

  • Cell-specific markers (when studying specific tissue contexts)

How does HMCN1 contribute to tumor progression and immune response in cancer?

HMCN1 has emerging roles in cancer biology with significant implications for tumor progression and immune responses:

• HMCN1 mutations in cancer:

  • Associated with higher tumor mutation burden (TMB) in clear cell renal cell carcinoma (ccRCC)

  • Correlated with improved prognosis in certain cancer types

  • Linked to metabolic pathway alterations in tumor cells

• HMCN1 in the tumor microenvironment:

  • Expressed by cancer-associated fibroblasts (CAFs) in ovarian cancer

  • Knockdown of HMCN1 in fibroblasts significantly reduces cancer cell invasion

  • Mediates interactions between stromal cells and tumor cells

• Immune system interactions:

• Signaling pathway involvement:

  • HMCN1 knockdown reduces RhoA/ROCK/MLC and cdc42 signaling

  • HMCN1 mutations associated with energy metabolism alterations

  • May influence TGF-β-mediated cytoskeletal rearrangements

What is the role of HMCN1 in basement membrane organization and tissue integrity?

HMCN1 plays critical roles in basement membrane organization and tissue integrity:

• Structural organization:

  • Forms track-like structures along basement membranes

  • Contributes to connecting adjacent basement membranes

  • Interacts with nidogens through its G2F domain

• Tissue-specific functions:

• Molecular interactions:

  • Direct binding to keratin 14 shown by yeast-2-hybrid, co-immunoprecipitation, and proximity ligation assays

  • Interacts with nidogen-1 and nidogen-2 through their TG3 domains

  • May facilitate cross-linking between different basement membrane components

• Pathological implications:

  • Deleterious HMCN1 variants aggravate epidermolysis bullosa simplex phenotype caused by KRT14 mutations

  • HMCN1 deficiency reduces keratin intermediate filament formation

  • Mutations impact protein stability and binding capabilities

How should researchers interpret contradictory findings about HMCN1 knockout phenotypes?

Research literature shows contradictory findings regarding HMCN1 knockout phenotypes that researchers should carefully interpret:

• Contradictory embryonic phenotypes:

  • Some studies reported preimplantation lethality in HMCN1 knockout mice

  • Multiple CRISPR/Cas9-generated Hmcn1-/- mice showed no embryonic phenotype and were viable and fertile

• Reconciling contradictions:

• Methodological considerations:

  • Genetic background differences between mouse strains

  • Different targeting strategies affecting different exons

  • Potential off-target effects depending on knockout method

  • Compensatory mechanisms through related family members

• Tissue-specific effects:

  • While gross phenotypes may be absent, subtle tissue-specific defects may exist

  • Under stress conditions or in disease models, phenotypes may become apparent

  • In human disorders, HMCN1 variants appear to act as modifiers rather than primary drivers

How can HMCN1 be effectively studied in the context of cancer biomarker research?

HMCN1 shows potential as a cancer biomarker that can be studied through various approaches:

• Mutation status analysis:

  • Correlation of HMCN1 mutations with tumor mutation burden (TMB)

  • Analysis of HMCN1 mutation frequency across different cancer types

  • Association of mutation status with clinical outcomes and treatment response

• Expression analysis:

• Functional biomarker validation:

  • Mechanistic studies linking HMCN1 to cancer hallmarks

  • Analysis of downstream pathway activation

  • Correlation with established biomarkers

• Clinical implementation considerations:

  • Integration with existing biomarker panels (e.g., TMB assessment)

  • Standardization of detection methods

  • Validation in prospective clinical cohorts

Based on recent research, HMCN1 may hold particular promise as a biomarker in bladder cancer, where a combination of TMB and HMCN1 expression status could provide increased prognostic value compared to TMB alone .

What are the main challenges in detecting full-length HMCN1 by Western blot?

Detection of full-length HMCN1 by Western blot presents significant technical challenges:

• Size-related issues:

  • The full-length protein (~613 kDa) is difficult to transfer efficiently

  • Standard gels may not adequately resolve proteins of this size

  • Multiple breakdown products or isoforms may complicate interpretation

• Technical solutions:

• Alternative approaches:

  • Expression of recombinant fragments spanning different domains

  • Immunoprecipitation followed by mass spectrometry

  • Use of epitope-tagged constructs for specific detection

• Observed molecular weights:

  • Full-length HMCN1: ~613 kDa

  • Major isoforms: ~600 kDa and ~60 kDa

  • Additional bands may represent proteolytic fragments or post-translational modifications

How can researchers effectively investigate HMCN1 protein-protein interactions?

Investigation of HMCN1 protein-protein interactions requires specialized approaches due to its large size and complex domain structure:

• Domain-specific interaction mapping:

  • Expression of recombinant HMCN1 fragments spanning different domains

  • Surface plasmon resonance (SPR) to measure binding affinities

  • Systematic testing against candidate binding partners

• In situ interaction detection:

• Functional validation approaches:

  • Mutation of key binding residues to disrupt specific interactions

  • Competition assays with blocking peptides or antibodies

  • Co-localization studies in tissue sections or cell cultures

• Known interaction partners:

  • Keratin 14: Direct binding shown by multiple methods

  • Nidogen-1 and Nidogen-2: Interaction through TG3 domains

  • RhoA signaling components: Functional interaction shown in invasion assays

What are the therapeutic implications of HMCN1 research in cancer and genetic disorders?

Recent research points to several potential therapeutic applications based on HMCN1 biology:

• Cancer therapeutic strategies:

  • Targeting HMCN1 in cancer-associated fibroblasts to reduce invasion

  • Exploiting HMCN1 mutation status to predict immunotherapy response

  • Using HMCN1 expression as a biomarker for patient stratification

• Genetic disorder applications:

• Technological approaches under development:

  • Antibody-based targeting of HMCN1 in disease contexts

  • Gene therapy to correct deleterious variants

  • Small molecule modulators of HMCN1-protein interactions

• Future research needs:

  • Better understanding of tissue-specific functions

  • Detailed mechanistic studies of HMCN1 in disease pathogenesis

  • Development of specific therapeutic modulators

How can multi-omics approaches advance our understanding of HMCN1 biology?

Integration of multiple omics approaches offers powerful strategies to elucidate HMCN1 biology:

• Integrated analysis strategies:

  • Correlation of HMCN1 mutation status with transcriptome alterations

  • Association of expression patterns with proteome changes

  • Integration with clinical outcomes data

• Multi-omics applications:

• Computational approaches:

  • Protein structure modeling and molecular dynamics simulations

  • Network analysis of HMCN1-associated pathways

  • Machine learning for biomarker development

• Single-cell applications:

  • Elucidation of cell type-specific expression patterns

  • Analysis of HMCN1's role in tumor microenvironment heterogeneity

  • Tracking of dynamic changes during disease progression